Payment Processing for Peptide Merchants: Product Evidence and Provider Restrictions

The word peptide does not describe one business model. A laboratory supplier selling specified materials to institutional buyers has a different customer journey from a pharmacy dispensing medicines, a consumer-facing store making human-use claims, or a clinic charging for consultations and treatment. A marketplace adds another question: is the contracting merchant selling the goods itself or collecting for other sellers?

Map the actual flow before choosing the application category. Name the entity that advertises, contracts with the customer, takes payment, fulfils the order and handles complaints. If those roles belong to different organisations, show the agreements and the route by which funds move between them.

A claim that the catalogue is research-only should be supported by how the business works, including buyer checks and what happens when an order appears inconsistent with that purpose. Copying the wording used by a different merchant does not establish the same operating model. Ask the provider which evidence it needs for your specific seller role and customer population; do not assume an application for ordinary ecommerce describes every part of the service.

Two FDA letters illustrate why a footer statement cannot be assessed in isolation. In its 31 March 2026 letter to Gram Peptides, FDA said website claims established intended human use despite research-use labelling. In its 24 August 2026 letter to Royal Peptides, FDA also referred to a peptide guide, a calculator and bacteriostatic water offered alongside products when explaining its findings. [1][2]

These are the agency's stated findings about the named businesses and the material it reviewed at those times. They are not a determination that all peptide products have the same status, or a statement about the businesses' subsequent remediation.

For your own review, preserve the product page, labels, advertisements, affiliate material, support scripts and linked educational pages together. Give contradictory material to the qualified reviewer rather than deleting it from the application pack and treating the question as resolved. Have a named person check what marketing partners publish on your behalf. The payment provider needs an accurate account of the business that customers encounter, including any claims that differ from the product description supplied during onboarding.

Create a stable internal reference for each catalogue item, including its advertised identity, form, pack size, supplier and intended buyer group. Connect that reference to the current product-page version and supporting documents. If suppliers, lots or labels change, retain the dates and the superseded versions so that an older order can still be reconstructed.

A certificate of analysis should be examined for the sample or batch it identifies, the laboratory, tests, methods, dates and stated limitations. Have the appropriate technical person assess what the report actually establishes. A percentage printed on a report does not answer whether the advertised use, customer market or payment arrangement is permitted. Those require different evidence and different reviewers.

The same care applies to claims about medicines. FDA's compounding Q&A distinguishes compounded drugs from FDA-approved drugs and generic drugs; it states that compounded drugs are not FDA-approved. [6] Do not use the name of an approved medicine or an ingredient as a substitute for checking the particular product and supply arrangement. This guide does not determine whether an individual compounded product can be supplied. Record that question for qualified review.

Avoid assuming that every provider either accepts all peptides or prohibits the entire category. Stripe's peptide FAQ describes conditional support, distinguishes pharmacy-related sales, and says research-purpose sales need preventive measures against non-research purchasing. It also says products with no specified purpose are assumed to be for human consumption. [3] That is Stripe's published policy, not an approval of your catalogue or an instruction for deciding whether a product needs a prescription.

PayPal's US Acceptable Use Policy separately requires pre-approval for prescription items and prescription-dispensing services and prohibits specified unlawful or consumer-safety-risk activity. [5] Neither an enabled wallet button nor a live account supplies the missing merchant-specific decision.

Adyen's policy explains that restrictions depend on business model and can also depend on jurisdiction and payment method. It expressly separates its agreement to provide service from an opinion on the legality of the products. [7] Use these sources to prepare precise questions: which entity, catalogue version, buyer group, customer markets and payment flows would the proposed arrangement cover? Record the answer and the unresolved items without converting a general policy statement into a verified acceptance badge.

Where research-purpose access is part of the proposed model, ask the provider what controls it expects and how exceptions should be handled. A self-declared purpose, a company email domain and a purchase order each provide different information. None should be treated as a complete assessment on its own.

Prepare a demonstration using fictional customer records. Show the information collected, who reviews it, the reasons an order can be held, and how a reviewer records a decision. Include an inconsistent case: for example, a purported institutional purchase whose support conversation describes a different intended use. The exercise should show escalation to the responsible reviewer, not a script that helps the buyer bypass the check.

Customer-access controls also create commercial trade-offs. More manual review may delay fulfilment and create support work; weak review may leave the provider unable to understand who is buying. Estimate the staffing needed at peak order volume. Tell customers the genuine order-review and delivery expectations before taking payment, and agree with the provider how authorisation, capture, cancellation and refunds should behave while a case is unresolved.

A launch decision should refer to a dated catalogue and website set, not just a broad industry label in an email. Ask which changes require a fresh assessment: new products, different forms, new intended uses, additional customer markets, a new supplier, or a move from selling your own goods to collecting for another seller. The exact notification and approval requirements belong in the provider's terms.

Build an internal change record with an owner, proposed effective date, affected items, specialist questions and the provider's response. Keep unresolved changes outside the active payment scope until the necessary decisions are made. This is a proposed merchant control, not a universal list of provider requirements.

Be candid about existing activity when moving providers. Stripe's prohibited-use policy includes misleading business information and processing for undisclosed merchants or products. [4] Changing the description of a transaction or putting it through a different company does not resolve an unanswered product question. A transparent scope may produce a smaller initial launch, but it gives operations, finance and the provider the same business to assess.

Select an example order and trace the item sold, catalogue version, applicable supplier or batch reference, buyer assessment, charge, fulfilment record and any complaint. Keep the provider's payment identifier alongside the order reference so that finance can locate a refund or dispute without needing access to the entire product file.

Define who handles a supplier-document problem, a missing parcel and a customer complaint about the product. These need different reviews. A successful card authorisation provides no answer about product quality, clinical suitability or whether an order should be released. Staff should know which specialist owns the relevant decision and what commercial action can be taken while it is pending.

Use access controls for sensitive records. An initial provider discussion should not become an uncontrolled email distribution of patient information, identity documents or unnecessary personal details. Agree the secure channel and document requirements with the recipient. For an internal demonstration, use redacted or fictional records and explain which source systems would supply the actual evidence. The objective is a traceable operation, not the largest possible attachment bundle.

Suppose a merchant has collected $6,000 from 40 orders of $150. Thirty orders have been delivered and ten remain unfulfilled during a supplier-document review. Four customers have requested refunds: two belong to the unfulfilled group and two have already received their orders. For planning, assume every unfulfilled order and both additional delivered-order refund requests will be refunded.

The amount to earmark under those assumptions is $1,800: ten unfulfilled orders plus two additional orders, each at $150. Adding $1,500 of unfulfilled orders to all $600 of refund requests would count two orders twice and produce $2,100. Track the affected order references before adding totals.

Now assume processing charges of $240 and a provider reserve of $600, with all remaining receipts available. Provider cash is $5,160; earmarking $1,800 leaves $3,360 before inventory, taxes and other operating costs. The reserve remains unavailable and is not assumed to satisfy those customer obligations. These are hypothetical amounts and management assumptions, not a provider quote, a determination of refund entitlement or a recommended reserve level. Replace them with actual contracts and order-level facts.

Give the provider an executive summary followed by a product register, ownership and entity records, relevant specialist conclusions, customer-market map and funds-flow description. Add the operational demonstration, fulfilment information and actual processing history if it exists. A startup should identify forecasts as forecasts rather than supplying invented volumes or past approvals.

In the product register, separate what is documented from what is awaiting an answer. A supplier file may establish provenance while leaving an intended-use or market question unresolved. A specialist opinion may address one product in one jurisdiction while leaving another item outside scope. Ask permission before circulating privileged or sensitive material; provide the provider with the evidence it is authorised to receive.

Request a proposal that states the service, contracting parties, covered activity, commercial terms, reserves, settlement conditions and responsibility for changes. No provider-specific rates, acceptance, reserve requirements or payout commitments were established for your business by the public sources in this guide. If the provider cannot explain the proposed scope, further investigation is more useful than installing another checkout.